- Home
- MIST vs MRNS Comparison
MIST vs MRNS Comparison
Compare MIST & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- MRNS
- Stock Information
- Founded
- MIST 2003
- MRNS 2003
- Country
- MIST Canada
- MRNS United States
- Employees
- MIST N/A
- MRNS N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- MRNS Health Care
- Exchange
- MIST Nasdaq
- MRNS Nasdaq
- Market Cap
- MIST 81.5M
- MRNS 104.7M
- IPO Year
- MIST N/A
- MRNS 2014
- Fundamental
- Price
- MIST $1.43
- MRNS $0.31
- Analyst Decision
- MIST Strong Buy
- MRNS Buy
- Analyst Count
- MIST 3
- MRNS 12
- Target Price
- MIST $13.00
- MRNS $4.56
- AVG Volume (30 Days)
- MIST 177.8K
- MRNS 5.7M
- Earning Date
- MIST 11-11-2024
- MRNS 11-05-2024
- Dividend Yield
- MIST N/A
- MRNS N/A
- EPS Growth
- MIST N/A
- MRNS N/A
- EPS
- MIST N/A
- MRNS N/A
- Revenue
- MIST N/A
- MRNS $30,263,000.00
- Revenue This Year
- MIST N/A
- MRNS $21.18
- Revenue Next Year
- MIST N/A
- MRNS $56.42
- P/E Ratio
- MIST N/A
- MRNS N/A
- Revenue Growth
- MIST N/A
- MRNS 16.56
- 52 Week Low
- MIST $1.12
- MRNS $0.26
- 52 Week High
- MIST $3.52
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- MIST 42.50
- MRNS 21.75
- Support Level
- MIST $1.41
- MRNS $0.29
- Resistance Level
- MIST $1.53
- MRNS $1.96
- Average True Range (ATR)
- MIST 0.07
- MRNS 0.12
- MACD
- MIST -0.01
- MRNS -0.18
- Stochastic Oscillator
- MIST 26.96
- MRNS 2.41
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.